Further investigation into how resistance develops is an essential prerequisite for finding a solution to this resistance problem so that targeted agents can be successfully integrated into the mainstream treatment of ALK-positive paediatric ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.